vs

Side-by-side financial comparison of ASP Isotopes Inc. (ASPI) and RAPID MICRO BIOSYSTEMS, INC. (RPID). Click either name above to swap in a different company.

ASP Isotopes Inc. is the larger business by last-quarter revenue ($16.7M vs $11.3M, roughly 1.5× RAPID MICRO BIOSYSTEMS, INC.). On growth, ASP Isotopes Inc. posted the faster year-over-year revenue change (1295.7% vs 37.3%). RAPID MICRO BIOSYSTEMS, INC. produced more free cash flow last quarter ($-3.3M vs $-47.4M).

ASP Isotopes Inc. is a specialty materials firm focused on developing and producing high-purity custom isotopes. Its products serve key sectors including nuclear medicine, targeted cancer therapies, advanced energy, and industrial research, with customers across North America, Europe and Asia Pacific.

Rapid Micro Biosystems, Inc. develops and manufactures automated microbial detection and quality control solutions for the life sciences industry. Its core products serve biopharmaceutical manufacturers, contract development and manufacturing organizations, operating across key global markets including North America, Europe and Asia-Pacific, helping clients cut testing timelines and improve operational efficiency.

ASPI vs RPID — Head-to-Head

Bigger by revenue
ASPI
ASPI
1.5× larger
ASPI
$16.7M
$11.3M
RPID
Growing faster (revenue YoY)
ASPI
ASPI
+1258.4% gap
ASPI
1295.7%
37.3%
RPID
More free cash flow
RPID
RPID
$44.1M more FCF
RPID
$-3.3M
$-47.4M
ASPI

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ASPI
ASPI
RPID
RPID
Revenue
$16.7M
$11.3M
Net Profit
$-12.5M
Gross Margin
12.5%
Operating Margin
-108.2%
Net Margin
-110.8%
Revenue YoY
1295.7%
37.3%
Net Profit YoY
-586.8%
-29.3%
EPS (diluted)
$-0.26

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ASPI
ASPI
RPID
RPID
Q4 25
$16.7M
$11.3M
Q3 25
$4.9M
$7.8M
Q2 25
$7.3M
Q1 25
$7.2M
Q4 24
$8.2M
Q3 24
$7.6M
Q2 24
$6.6M
Q1 24
$5.6M
Net Profit
ASPI
ASPI
RPID
RPID
Q4 25
$-12.5M
Q3 25
$-12.9M
$-11.5M
Q2 25
$-11.9M
Q1 25
$-11.3M
Q4 24
$-9.7M
Q3 24
$-11.3M
Q2 24
$-12.6M
Q1 24
$-13.3M
Gross Margin
ASPI
ASPI
RPID
RPID
Q4 25
12.5%
Q3 25
8.7%
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Operating Margin
ASPI
ASPI
RPID
RPID
Q4 25
-108.2%
Q3 25
-306.1%
-145.1%
Q2 25
-167.3%
Q1 25
-161.8%
Q4 24
-124.5%
Q3 24
-158.3%
Q2 24
-202.1%
Q1 24
-254.4%
Net Margin
ASPI
ASPI
RPID
RPID
Q4 25
-110.8%
Q3 25
-263.7%
-146.8%
Q2 25
-163.3%
Q1 25
-156.3%
Q4 24
-117.6%
Q3 24
-148.9%
Q2 24
-190.1%
Q1 24
-237.4%
EPS (diluted)
ASPI
ASPI
RPID
RPID
Q4 25
$-0.26
Q3 25
$-0.15
$-0.26
Q2 25
$-0.27
Q1 25
$-0.26
Q4 24
$-0.22
Q3 24
$-0.26
Q2 24
$-0.29
Q1 24
$-0.31

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ASPI
ASPI
RPID
RPID
Cash + ST InvestmentsLiquidity on hand
$333.3M
$20.0M
Total DebtLower is stronger
$14.4M
Stockholders' EquityBook value
$204.2M
$33.2M
Total Assets
$498.0M
$74.9M
Debt / EquityLower = less leverage
0.07×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ASPI
ASPI
RPID
RPID
Q4 25
$333.3M
$20.0M
Q3 25
$113.9M
$18.9M
Q2 25
$18.3M
Q1 25
$18.9M
Q4 24
$16.9M
Q3 24
$22.0M
Q2 24
$37.1M
Q1 24
$22.4M
Total Debt
ASPI
ASPI
RPID
RPID
Q4 25
$14.4M
Q3 25
$13.9M
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Stockholders' Equity
ASPI
ASPI
RPID
RPID
Q4 25
$204.2M
$33.2M
Q3 25
$74.1M
$44.3M
Q2 25
$54.5M
Q1 25
$65.5M
Q4 24
$75.4M
Q3 24
$84.4M
Q2 24
$94.6M
Q1 24
$105.9M
Total Assets
ASPI
ASPI
RPID
RPID
Q4 25
$498.0M
$74.9M
Q3 25
$225.9M
$84.4M
Q2 25
$75.6M
Q1 25
$85.4M
Q4 24
$98.2M
Q3 24
$105.8M
Q2 24
$117.1M
Q1 24
$127.7M
Debt / Equity
ASPI
ASPI
RPID
RPID
Q4 25
0.07×
Q3 25
0.19×
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ASPI
ASPI
RPID
RPID
Operating Cash FlowLast quarter
$-37.8M
$-3.2M
Free Cash FlowOCF − Capex
$-47.4M
$-3.3M
FCF MarginFCF / Revenue
-284.7%
-29.6%
Capex IntensityCapex / Revenue
57.9%
0.8%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-31.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ASPI
ASPI
RPID
RPID
Q4 25
$-37.8M
$-3.2M
Q3 25
$-8.9M
$-9.1M
Q2 25
$-9.7M
Q1 25
$-9.1M
Q4 24
$-9.9M
Q3 24
$-8.6M
Q2 24
$-10.1M
Q1 24
$-15.5M
Free Cash Flow
ASPI
ASPI
RPID
RPID
Q4 25
$-47.4M
$-3.3M
Q3 25
$-12.0M
$-9.1M
Q2 25
$-10.1M
Q1 25
$-9.4M
Q4 24
$-10.0M
Q3 24
$-8.8M
Q2 24
$-10.6M
Q1 24
$-16.1M
FCF Margin
ASPI
ASPI
RPID
RPID
Q4 25
-284.7%
-29.6%
Q3 25
-245.5%
-116.4%
Q2 25
-138.6%
Q1 25
-130.2%
Q4 24
-121.8%
Q3 24
-116.0%
Q2 24
-159.8%
Q1 24
-287.1%
Capex Intensity
ASPI
ASPI
RPID
RPID
Q4 25
57.9%
0.8%
Q3 25
64.4%
0.9%
Q2 25
5.0%
Q1 25
4.4%
Q4 24
1.2%
Q3 24
2.9%
Q2 24
6.9%
Q1 24
10.4%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ASPI
ASPI

Segment breakdown not available.

RPID
RPID

Products$9.3M83%
Services$2.0M17%

Related Comparisons